NVAX - Novavax, Inc.
| Previous Close | 6.43 |
| Open | 6.29 |
| Bid | 5.02 x 1100 |
| Ask | 7.30 x 3200 |
| Day's Range | 5.82 - 6.56 |
| 52 Week Range | 5.72 - 51.60 |
| Volume | 2,036,409 |
| Avg. Volume | 1,106,467 |
| Market Cap | 138.489M |
| Beta (3Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.37 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.14 |
- Motley Fool•4 days ago
Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
- GlobeNewswire•10 days ago
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
GAITHERSBURG, Md., May 10, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes.
- Thomson Reuters StreetEvents•10 days ago
Edited Transcript of NVAX earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 Novavax Inc Earnings Call
- American City Business Journals•11 days ago
How Novavax plans to advance after failed drug trial, delisting threat
The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.
- GlobeNewswire•12 days ago
Novavax Announces Reverse Stock Split of Common Stock
Novavax, Inc. (NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of Incorporation (the Amended Certificate) to effect the reverse stock split at a Special Meeting of Stockholders held on May 8, 2019. The reverse stock split is intended to give Novavax greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.
- Motley Fool•13 days ago
Why Novavax Stock Is Fading Today
Novavax's proposed reverse split has investors on edge.
Market Realist•13 days agoNanoFlu Vaccine Could Be Big Growth Opportunity for Novavax
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple
Market Realist•13 days agoWill the ResVax Vaccine Be Key Revenue Driver for Novavax?
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the
- Market Realist•14 days ago
What Analysts Are Recommending for Novavax after Q1 Results
Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million
- Insider Monkey•14 days ago
Here’s What Hedge Funds Think About Novavax, Inc. (NVAX)
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
- Motley Fool•17 days ago
Is Novavax a Buy?
Novavax's first-quarter earnings report didn't provide the answers investors were looking for.
Motley Fool•17 days agoNovavax Inc (NVAX) Q1 2019 Earnings Call Transcript
NVAX earnings call for the period ending March 31, 2019.
- Zacks•17 days ago
Novavax (NVAX) Reports Q1 Loss, Misses Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 8.33% and -17.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•17 days ago
Novavax: 1Q Earnings Snapshot
The Gaithersburg, Maryland-based company said it had a loss of 11 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Zacks•18 days ago
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
- GlobeNewswire•19 days ago
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
GAITHERSBURG, Md., May 01, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and.
- Zacks•19 days ago
What's in the Cards for Novavax (NVAX) This Earnings Season?
Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
- GlobeNewswire•25 days ago
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
GAITHERSBURG, Md., April 25, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of.
- Zacks•25 days ago
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
- Zacks•26 days ago
Should You Buy Lottery Stocks?
Like playing the lottery, some stocks lure in investors with the promise of possible riches.
- Benzinga•last month
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
- American City Business Journals•last month
Novavax faces delisting threat following failed drug trial
Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Novavax, Inc.
NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Levi & Korsinsky announces it has commenced an investigation of Novavax, Inc. (NASDAQ: NVAX) concerning possible breaches of fiduciary duty. To obtain additional ...
